<DOC>
	<DOCNO>NCT00740831</DOCNO>
	<brief_summary>This trial ass efficacy safety PGL4001 versus GnRH agonist , 3-month period pre-operative treatment pre-menopausal woman suffer excessive uterine bleeding due uterine myoma .</brief_summary>
	<brief_title>PGL4001 Versus GnRH-agonist Uterine Myomas</brief_title>
	<detailed_description />
	<mesh_term>Myoma</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Be premenopausal woman 18 50 year inclusive . Have excessive uterine bleeding due myoma Have myomatous uterus least one myoma ≥ 3 cm diameter size Be eligible one surgical procedure : e.g . hysterectomy , myomectomy others . If childbearing potential subject must practice nonhormonal method contraception . Have Body Mass Index ( BMI ) ≥ 18 ≤ 40 . Has history current uterine , cervical , ovarian breast cancer . Has history current endometrium atypical hyperplasia adenocarcinoma . Has know severe coagulation disorder . Has history current treatment myoma Selective Progesterone Receptor Modulator ( SPRM ) GnRHagonist . Has history know current osteoporosis . Has abnormal hepatic function study entry . Has positive pregnancy test baseline nursing planning pregnancy course study . Has current ( within twelve month ) problem alcohol drug abuse . Is currently enrol investigational drug device study participate study within last 30 day .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Uterine Myomas</keyword>
</DOC>